WB-308

WB-308

• CAS Number: 1373764-87-4
• UNSPSC Description: WB-308 is a novel small molecule that was identified as an inhibitor of EGFR by an in vitro EGFR kinase activity system. WB-308 was able to reduce the proliferation and clonogenicity of NSCLC cells, causing G2/M phase arrest and apoptosis. In addition, WB-308 inhibited tumor growth in two in vivo animal models (lung orthotopic transplantation model and patient-derived clonal mouse model). WB-308 impaired the phosphorylation of EGFR, AKT, and ERK1/2 proteins. Compared with Gefitinib, WB-308 had lower cytotoxicity. This study showed that WB-308 is a new EGFR-TKI that may be considered as an alternative to Gefitinib in the clinical treatment of NSCLC.
• Target Antigen: Others
• Type: Reference compound
• Related Pathways: Others
• Applications: Cancer-programmed cell death
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/wb-308.html
• Smiles: FC1=CC2=C(C=C1)NC3=C2CCN(C3)C(CC4=CC=CC=C4)=O
• Molecular Weight: 308.35
• References & Citations: [1]Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported